Unicycive's Q2 2026 Filing: Second OLC CRL, $13.8M Cash Burn, and $61.4M Runway
UNCY sits 35% above its 52-week low of $3.71 on light trading volume (0.3× avg).
Summary
Unicycive's Q2 2026 filing reveals a second CRL for OLC and a $13.8M operating cash burn, offset by $34.0M in ATM proceeds. Cash and securities of $61.4M provide a 12-month runway.
Key Events · Earnings and Guidance · UNCY
-
Second CRL for OLC
On June 30, 2026, the FDA issued a second Complete Response Letter for oxylanthanum carbonate, once again citing third-party manufacturing deficiencies. No clinical or safety issues were raised.
-
Cash Burn and Runway
Operating cash outflow reached $13.8M in H1 2026. As of June 30, 2026, cash and marketable securities totaled $61.4M, which management believes funds operations for at least 12 months.
-
ATM Proceeds
During H1 2026, the company sold 5.3M shares under its ATM program at an average price of $6.64, raising $34.0M net of commissions.
-
Non-Cash Warrant Gain
A $3.2M non-cash gain from the decrease in warrant liability—to $13.7M from $16.9M—reduced the reported net loss to $14.5M for H1 2026.
Analysis · UNCY · Life Sciences
The Q2 2026 10-Q from Unicycive discloses a second Complete Response Letter for its lead drug OLC, received on June 30, 2026, again pointing to the same third-party manufacturing deficiencies. With no approved products and no revenue, the company burned $13.8 million in operating cash during the first half. That drain was partially offset by $34.0 million raised through ATM sales at an average price of $6.64 per share—well above today's $4.99. Cash and marketable securities stand at $61.4 million, which management says is enough to fund operations for at least 12 months. A decline in the warrant liability from $16.9 million to $13.7 million produced a non-cash gain of $3.2 million, trimming the reported net loss to $14.5 million. The second CRL intensifies the regulatory overhang and raises the stakes for the remaining cash runway.
At the time of this filing, UNCY was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $3.71 to $8.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.